Skip to main content

Advertisement

SpringerLink
Log in

Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We studied the toxicity and efficacy of adding in sequence 4 resistance modulators to combination chemotherapy and radiotherapyin the treatment of glioblastoma multiforme and poor prognosis anaplastic astrocytomas. Patients received cisplatin plus mitomycin-C concurrently with and following 60 Gy of radiotherapyadministered over 6 weeks. Resistance modulators were added in sequence to chemotherapy in each cohort of 6 patients as follows: metronidazole + pentoxifylline (cohort 1); + dipyridamole(cohort 2); + beta carotene (cohort 3). Central nervous system toxicity (which ranged from drowsiness to seizures and lossof consciousness) was frequent. The incidence of gastrointestinal symptoms was substantial, but was usually mild to moderatein severity. Three of 11 patients evaluable for response achieved a partial remission with treatment. The median survival duration for all patients was 26 weeks from initial diagnosis. The study was terminated prematurely because of significant toxicity (in this study as well as in parallel concurrent studies of similar design in other tumor types) and apparent lack of benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stewart DJ: The role of chemotherapy in the treatment of gliomas in adults. Can Treat Rev 16: 129–160, 1989

    Google Scholar 

  2. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 (8): 2585–2597, 1993

    Google Scholar 

  3. Teicher BA, Holden SA, Al-Achi A, Herman TS: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivoin the FSa II C murine fibrosarcoma. Cancer Res 50: 3339–3344, 1990

    Google Scholar 

  4. Fu KK, Rayner PA, Lam KN: Modification of the effects of continuous chemotherapy infusion. Int J Rad Oncol Biol Phys 10: 1473–1478, 1984

    Google Scholar 

  5. Rauth AM, Mohindra JK, Rannock IF: Activity of mitomycin-C for aerobic and hypoxic cells in vitroand in vivo. Cancer Res 43: 4154–4158, 1983

    Google Scholar 

  6. Scholds C: Personal communication, 1994

  7. Douple EB, Richmond RC: Platinum complexes as radio-sensitizers of hypoxic mammalian cells. Br J Cancer 37: 98–102, 1978

    Google Scholar 

  8. Decker DA, Kinzie J, Evans R, Abu-zahra H, Al-Sarraf M: Pilot study of combination 5-fluorouracil, cisdiamminedichloroplatinum II, and radiation therapy for grade III and IV astrocytomas. Am J Clin Oncol (CCT) 10 (5): 444–447, 1987

    Google Scholar 

  9. Feun LG, Stewart DJ, Maor M, Leavens M, Savaraj N, Burgess MA, Yung WKA, Benjamin RS: A pilot study of cisdiamminedichloroplatinum and radiotherapy in patients with high grade astrocytomas. J Neuro-Oncol 1: 109–113, 1983

    Google Scholar 

  10. Durand RD: Synergism of cisplatin and mitomycin-C in sensitive and resistant cell subpopulations of a tumor model. Int J Cancer 44: 911–917, 1989

    Google Scholar 

  11. Zijlstra JG, De Vries EGE, Mulder NH: Multifactorial drug resistance in adriamycin-resistant human small cell lung carcinoma cell line. Can Res 47: 1780–1784, 1987

    Google Scholar 

  12. Mansouri A, Kurt JH, Nagle WA: Tumor drug-resistance: A challenge to therapist and biologists. Am J Med Sci 307: 438–444, 1994

    Google Scholar 

  13. Stewart DJ, Evans WK: Non-chemotherapeutic agents potentiate chemotherapy efficacy. Cancer Treat Rev 16: 1–40, 1989

    Google Scholar 

  14. Clement JJ, Johnson RK: Evaluation of radiosensitizers in combination with chemotherapeutic agents in solid tumors. Int J Rad Oncol Biol Phys 8: 631–634, 1982

    Google Scholar 

  15. Roizin-Towle LA, Hall EJ: Enhanced cytotoxicity of antineoplastic agents following prolonged exposure to misonidazole. Br J Cancer 44: 202–207, 1981

    Google Scholar 

  16. Siemann DW, Hill SA: Enhanced tumor responses through therapies combining CCNU, miso and radiation. Int J Radiat Oncol Biol Phys 10: 1623–1626, 1984

    Google Scholar 

  17. Siemann DW, Maddison K, Wolf K, Hill SA, Keng PC: In vivointeraction between radiation and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the absence or presence of misonidazole in mice. Cancer Res 45: 198–202, 1985

    Google Scholar 

  18. Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B: Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitroand in vivo. Anticancer Res 11: 1555–1560, 1991

    Google Scholar 

  19. Boike GM, Petru E, Sevin B-U, Averette HE, Chou R-C, Penalver M, Donato D, Schiano M, Hilsenbeck SG, Perras J: Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gyn Oncol 38: 315–322, 1990

    Google Scholar 

  20. Boike G, Young J, Sightler S, Averette H: Phase I pharmacokinetic study of escalating pentoxifylline with cisplatin in recurrent gynecologic (gyn) cancers. Proc AACR 33: A1330, 1992

    Google Scholar 

  21. Kyriazis AP, Kyriazis AA, Yagoda A: Enhanced therapeutic effect of cis-diamminedichloroplatinum II against nude mouse grown human pancreatic adenocarcinoma when combined with 1-a-D-Arabinofuranosylcytosine and caffeine. Cancer Res 45: 6083–6087, 1985

    Google Scholar 

  22. Fingert HJ, Alley MC, Lieber MM, Pardee AB: Enhanced lethality by methylxanthines in human bladder cancer cells treated with thiotepa or mitomycin-C. Proc AACR 25: 354, 1984

    Google Scholar 

  23. Aviado DM, Dettelback HR: Pharmacology of pentoxifylline a hemorheologic agent for the treatment of intermittent claudication. Angiology 35: 407–417, 1984

    Google Scholar 

  24. Nakagawa M, Yamaguchi T, Ueda H, Shirishi N, Komiyama S, Akiyama S, Ogata J, Kuwano M: Potentiation by vitamin A of the action of anticancer agents against murine tumors. Jpn J Cancer Res (Gann) 76: 887–894, 1985

    Google Scholar 

  25. Rutka JT, De Armond SJ, Giblin J, McCulloch JR, Wilson CB, Rosenblum ML: Effects of retinoids on the proliferations, morphology and expression of glial fibrillary acidic protein of an anaplastic astrocytoma cell line. Int J Cancer 42: 419–427, 1988

    Google Scholar 

  26. Boone CW, Kelloff GJ, Malone WE: Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 50: 2–9, 1990

    Google Scholar 

  27. Howell SB, Vick J, Andrews PA. Biochemical modulation of cisplatin by dipyridamole. Proc AACR 28: 313, 1987

    Google Scholar 

  28. Stewart DJ, Goel R, Verma S, Perrault D, Cripps C: Carboplatin plus multiple resistance modulators. Proc AACR: A1405, 1992

  29. Stewart DJ, Goel R, Huan SD, Cripps MC, Yau JC, Soltys K, Prosser A, Bourcier J, Paul M, Evans WK, Gallant G: Etoposide plus multiple resistance modulators. Proc ASCO 12: A407, 1993

    Google Scholar 

  30. Stewart DJ, Goel R, Dahrouge S, Yau J, Tomiak E, Huan S, Cripps MC: Epirubicin plus multiple chemotherapy resistance modulators in the treatment of resistant malignancies. Cancer Chemather Pharmacol. In Press

  31. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and combined postoperative radiotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997–1007, 1983

    Google Scholar 

  32. EORTC Brain Tumor Group: Cisplatin does not enhance the effect of radiation therapy in malignant gliomas. Eur J Cancer 27 (5): 571–575, 1991

    Google Scholar 

  33. Grem JL, Fischer PH: Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 46: 6191–6199, 1986

    Google Scholar 

  34. Carlson RW, Coleman CN, Kohler M, Gribble MH, Halsey J: A randomized phase II study of L-PAM versus L-PAM + the chemosensitizer misonidazole (MISO) for non-small cell lung cancer (NSCLC): a Northern California Oncology Groups study. Proc ASCO 6: 28, 1987

    Google Scholar 

  35. Webster LT Jr: Drugs used in the chemotherapy of protozoal infections. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 8th ed., Pergamon Press, New York, NY 999–1007, 1990

    Google Scholar 

  36. Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474–2479, 1982

    Google Scholar 

  37. Stewart DJ, Richard M, Hugenholtz HN, Benoit B, Russell N, Dennery J, Peterson E, Maroun JA: Cisplatin plus cytosine arabinoside in adults with malignant gliomas. J Neuro-Oncol 2: 29–34, 1984

    Google Scholar 

  38. Stewart DJ, Benoit B, Hugenholtz H, Maroun JA, Russell N, Richard MT, Peterson E, Dennery J, Nabwangu JF, Grahovac Z, Belanger G, Assang W, Hopkins HS, Girard A: Cisplatin, arabinofuranosyl cytosine, and caffeine before radiation for glioblastomas. In: Walker MD, Thomas DGT (eds) Biology of Brain Tumor, Martinus Nijhoff Publishers, Boston 393–398, 1986

    Google Scholar 

  39. Rutka JT, De Armond SJ, Giblin J, McCulloch JR, Wilson CB, Rosenblum ML: Effect of retinoids on the proliferation, morphology and expression of glial fibrillary acidic protein of an anaplastic astrocytoma cell line. Int J Cancer 42: 419–427, 1988

    Google Scholar 

  40. Ali-Osman F, Berger MS, Rajagopal S, Spence A, Livingston RB: Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res 53: 5663–5668, 1993

    Google Scholar 

  41. Robert J, Huet S, Bennis S, Chapey C: Comparison of twelve MDR modulating agents in a model of doxorubicin-resistant rat glioblastoma cells in vitro. 4th Internation Congress of Anti-Cancer Chemotherapy, February 2–5, 1993, Paris, France

  42. Urtasun RC, Band P, Chapman JD, Feldstein ML, Mielke B, Fryer C: Radiation and high dose metronidazole in supratentorial glioblastomas. N Eng J Med 294: 1364–1367, 1976

    Google Scholar 

  43. Dische S: Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy. Radiother Oncol 3: 97–115, 1985

    Google Scholar 

  44. Stewart DJ, Benoit B, Richard MT, Hugenholtz H, Dennery J, Russell N, Peterson E, Grahovac Z, Belanger G, Maroun JA, Young V: Treatment of malignant gliomas in adults with BCNU plus metronidazole. J Neuro-Oncol 2: 53–58, 1984

    Google Scholar 

  45. Stewart DJ, Raaphorst P, Yau J, Beaubien A: Active vs passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 14: 115–130, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Centre, Canada

    David J. Stewart, Simone Dahrouge, Olu Agboola & André Girard

  2. Faculty of Medicine, the University of Ottawa, Ottawa, Ontario, Canada

    David J. Stewart, Simone Dahrouge, Olu Agboola & André Girard

Authors
  1. David J. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simone Dahrouge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olu Agboola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. André Girard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, D.J., Dahrouge, S., Agboola, O. et al. Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. J Neurooncol 32, 161–168 (1997). https://doi.org/10.1023/A:1005788121043

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005788121043

Search

Navigation